Association Between Time‐In‐Therapeutic Range of Calcineurin Inhibitor Trough Level and Short‐Term Outcomes of Recipients After Adult Living‐Donor Liver Transplantation
Journal of Hepato-Biliary-Pancreatic Sciences · 2025
DOI: 10.1002/jhbp.70046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2025. Verfasst von Ryugen Takahashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Artificial Organ and Transplantation Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Jap…. Hauptthemen laut MEDLINE: Liver Transplantation, Calcineurin Inhibitors, Living Donors, Graft Rejection. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Time‐in therapeutic range (TTR) is defined as the time a drug concentration remains within the therapeutic range. To explore the optimal management of calcineurin inhibitor (CNI), we investigated how TTR percentage (TTR%) in two different CNI protocols relates to short‐term outcomes after living‐donor liver transplantation (LDLT).
Methods
TTR% was estimated for two different protocols in 352 adult LDLT recipients over 90 days in this retrospective, single‐center study. Short‐term outcomes were compared among the TTR% groups in each protocol.
Results
Higher TTR% was associated with better acute rejection‐free survival: 96.2%, 86.1%, 74.7%, and 38.9% for TTR% ≥ 60%, ≥ 50%–< 60%, ≥ 40%–< 50%, and < 40%, in the low‐target protocol, respectively ( p < 0.001, log‐rank test); 73.7%, 74.3%, 63.6%, and 48.3%, in the high‐target protocol, respectively ( p = 0.003). The incidence of adverse events was similar among TTR% groups in each protocol. Multivariate analysis revealed higher TTR% was protective for rejection‐free survival, and this trend was particularly pronounced in the low‐target protocol.
Conclusions
High TTR%, reflecting well‐controlled CNI levels, was associated with better outcomes after LDLT. The outcome of high TTR% in low‐target protocol seems better, but further prospective validation is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Artificial Organ and Transplantation Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
ORCID-Profile: Nobuhisa Akamatsu, Kiyoshi Hasegawa
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Takahashi, R., Akamatsu, N., Saruta, Y., Nakamura, M., Nishioka, Y., Mihara, Y., Ichida, A., Takamoto, T., Kawaguchi, Y., & Hasegawa, K. (2025). Association Between Time‐In‐Therapeutic Range of Calcineurin Inhibitor Trough Level and Short‐Term Outcomes of Recipients After Adult Living‐Donor Liver Transplantation. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.70046
Vancouver
Takahashi R, Akamatsu N, Saruta Y, Nakamura M, Nishioka Y, Mihara Y, et al. Association Between Time‐In‐Therapeutic Range of Calcineurin Inhibitor Trough Level and Short‐Term Outcomes of Recipients After Adult Living‐Donor Liver Transplantation. Journal of Hepato-Biliary-Pancreatic Sciences. 2025. doi:10.1002/jhbp.70046
BibTeX
@article{Takahashi2025,
author = {Takahashi, Ryugen and Akamatsu, Nobuhisa and Saruta, Yuya and Nakamura, Mei and Nishioka, Yujiro and Mihara, Yuichiro and Ichida, Akihiko and Takamoto, Takeshi and Kawaguchi, Yoshikuni and Hasegawa, Kiyoshi},
title = {Association Between Time‐In‐Therapeutic Range of Calcineurin Inhibitor Trough Level and Short‐Term Outcomes of Recipients After Adult Living‐Donor Liver Transplantation},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2025},
doi = {10.1002/jhbp.70046}
}
EUVIMED